Introduction
Achieving Generally Recognized as Safe (GRAS) status in the United States is a critical step for companies seeking to bring food ingredients to market. A core component of any GRAS determination is the scientific evaluation of safety, which is often supported by toxicological data. However, unlike prescriptive regulatory frameworks, the U.S. FDA adopts a case-by-case, risk-based approach, meaning that the type and extent of toxicological studies required can vary significantly depending on the substance.
Key factors such as chemical characteristics, intended use, and estimated exposure levels play a decisive role in shaping the testing strategy. As a result, companies must go beyond a checklist mindset and instead develop a science-driven, fit-for-purpose toxicological assessment that aligns with regulatory expectations.
This article provides an overview of the common types of toxicological studies used in GRAS evaluations, outlines the FDA’s guiding principles for study selection, and explains how businesses can design an effective strategy to support a successful GRAS submission.
Common Toxicological Study Types and Associated Requirements
Common types of toxicological studies and their associated requirements are summarized below.
Acute Toxicity Studies
Acute toxicity studies characterize the acute toxicity profile and provide dosage guidance for dose-range finding in subsequent repeated-dose studies. These studies are typically conducted via the oral route to assess the effects following a single exposure or multiple exposures within a 24-hour period.
Subchronic Toxicity Studies
Subchronic toxicity studies assess the adverse effects associated with repeated exposure over an extended period, typically lasting 90 days. These studies are essential for determining the no-observed-adverse-effect level (NOAEL) and are generally performed via the oral route in test animals.
Chronic Toxicity Studies
Chronic toxicity studies evaluate the long-term adverse effects and potential carcinogenicity of a substance. For substances associated with high exposure levels or those intended for long-term dietary use, such studies, which typically span one to two years, may be required.
Genotoxicity Studies
Genotoxicity studies assess the potential of a substance to induce gene mutations, chromosomal aberrations, or DNA damage, serving as important indicators of potential carcinogenicity. These studies typically follow a battery-testing approach, including both in vitro assays and in vivo assays to address potential DNA reactivity and chromosomal damage.
Reproductive and Developmental Toxicity Studies
Reproductive and developmental toxicity studies evaluate the effects of a substance on reproductive function, embryogenesis, fetal development, and postnatal growth. These studies generally encompass fertility and early embryonic development studies, embryo-fetal developmental toxicity studies, and pre- and postnatal developmental toxicity studies.
Carcinogenicity Studies
Carcinogenicity studies assess the tumorigenic potential of a substance following long-term exposure, typically spanning a period of two years. Such studies may be necessary for substances with structural features indicative of carcinogenic risk, positive genotoxicity test results, proliferative lesions observed in long-term toxicity studies, or for those with anticipated high exposure levels.
Specialized Toxicological Studies
While not required for every GRAS notice, additional specialized studies may be required depending on the specific properties and intended use of the substance. These may include immunotoxicity studies, neurotoxicity studies, allergenicity studies, and ADME (absorption, distribution, metabolism, excretion) studies. For substances derived from proteins or microorganisms, particular attention should be given to evaluating potential allergenic risks. ADME studies provide pivotal pharmacokinetic data that justify species selection and support the biological relevance of findings in other toxicological studies.
Guiding Principles for Conducting Toxicological Studies
The U.S. FDA does not issue a prescribed list of toxicological studies that must be conducted for a GRAS submission. Rather, its guidance emphasizes a case-by-case approach and recommends a framework for data evaluation. These principles are primarily set forth in the FDA's Guidance for Industry and Other Stakeholders: Toxicological Principles for the Safety Assessment of Food Ingredients (commonly referred to as the Redbook).
The selection of toxicological studies under the FDA's framework is guided by the following factors:
Characteristics of the Substance
Considerations include whether the chemical structure is analogous to that of known toxic substances; for substances derived from natural sources (e.g., plants or microorganisms), the safety of the source and potential contaminants or impurities introduced during extraction should be assessed; and whether the substance contains potentially harmful impurities, including but not limited to heavy metals, residual solvents, or microbial toxins.
Existing Safety Data and Literature
This encompasses all available, peer-reviewed scientific literature, including prior toxicological studies, ADME data, and human clinical studies. If existing data are sufficiently robust to support a conclusion of safety under the intended conditions of use, new toxicological studies may not be necessary. Conversely, when data gaps or deficiencies are identified, additional studies may be required to address them.
Intended Use and Exposure Levels
If exposure levels are sufficiently low, a limited set of toxicological data including genotoxicity and subchronic toxicity studies, may be adequate to demonstrate safety. For substances with higher exposure levels or those intended for broad use in the daily food supply, more comprehensive and longer-term studies, such as chronic toxicity or carcinogenicity studies, may be warranted to exclude potential adverse effects.
In summary, there is no fixed testing battery for toxicological studies in GRAS assessments. The approach is grounded in a science-based risk evaluation. The FDA's guidance calls for the use of recognized methodologies to submit sufficient, high-quality scientific evidence that demonstrates safety under the intended conditions of use. This requires a comprehensive and systematic evaluation, rather than simply a combination of standard toxicological tests.
Once a robust safety assessment has been established—supported by appropriate toxicological data—the next step is to determine how the GRAS conclusion will be used from a regulatory perspective. In the United States, companies may either rely on a self-affirmed GRAS conclusion or choose to notify the FDA through a formal submission.
How to Apply for GRAS?
In principle, any organization or individual may pursue GRAS status through one of the following two pathways:
Self-Affirmed GRAS
A qualified panel of experts conducts the safety evaluation of the substance and renders a conclusion of safety, without any requirement to notify or consult the FDA. The resulting information is kept internal to the company.
FDA-Notified GRAS
The company submits a GRAS dossier to the FDA for review. The safety conclusion must be based on publicly available scientific evidence, ensuring that the consensus is generally recognized by qualified experts in the field. The FDA evaluates the submission and, if in agreement, issues a "no questions" letter. It is important to note that an FDA-notified GRAS determination typically incorporates the conclusions of the expert panel from the self-affirmed GRAS assessment as part of the dossier.
How REACH24H Supports Your GRAS Submission
Highly experienced in GRAS submissions and backed by U.S.-based expert resources, REACH24H helps applicants develop a tailored testing strategy that minimizes costs, shortens the submission timeline, and facilitates successful market entry into the United States.
For more information or assistance, please feel free to contact us at customer@reach24h.com.
